Author: Faron Pharmaceuticals

Posted Date:

May 13, 2026

Faron to Present New BEXMAB Translational and Clinical Data in HR-MDS at EHA 2026

Faron Pharmaceuticals

May 13, 2026
Faron Pharmaceuticals Ltd: Termination of Liquidity Provision Service

Faron Pharmaceuticals

May 6, 2026
Faron Pharmaceuticals Ltd: Holding(S) In Company

Faron Pharmaceuticals

May 5, 2026
Faron Pharmaceuticals Ltd: Directorate Appointment

Faron Pharmaceuticals

May 5, 2026
Faron Pharmaceuticals Ltd: Results of the Annual General Meeting

Faron Pharmaceuticals

May 4, 2026
Faron Pharmaceuticals Ltd: Holding(s) in Company

Faron Pharmaceuticals

April 22, 2026
Faron Pharmaceuticals Ltd: Holding(S) In Company

Faron Pharmaceuticals

April 20, 2026
Faron Pharmaceuticals LTD: Holding(s) in Company

Faron Pharmaceuticals

April 16, 2026
Faron Announces Collaboration with Parexel to Support Phase IIb BEXERA Trial in Treatment-Naïve HR-MDS

Faron Pharmaceuticals

April 16, 2026
Notice of Faron Pharmaceuticals LTD’s Annual General Meeting

Faron Pharmaceuticals

April 10, 2026